New clinical trial in patients suffering from tumors harboring NRG1 gene alterations, specifically NRG1 gene fusion-positive advanced solid tumors.
To learn more about a prospective real-world outcomes study in patients with tumors harboring NRG1 fusions, click here.
Posted on 12/09/2021.
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
